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Nonlinear mixed-effect models are used increasingly during drug development. For design,
an alternative to simulations is based on the Fisher information matrix. Its expression was
derived using a first-order approach, was then extended to include covariance and imple-
mented into the R function PFIM. The impact of covariance on standard errors, amount of
information and optimal designs was studied. It was also shown how standard errors can be
predicted analytically within the framework of rich individual data without the model. The
results were illustrated by applying this extension to the design of a pharmacokinetic study
of a drug in paediatric development.
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1 INTRODUCTION
Nonlinear mixed-effect models (NLMEM) are used increasingly during drug development
for the analysis of dose-concentration-response data. They allow for a sparse sampling design
with few data points per individual in a set of individuals and estimation of mean parame-
ters, their inter-individual variability and covariate effects. This can be particularly useful
in clinical trials with specific populations, such as children (Tod et al., 2008), where classical
studies with a large number of samples are often limited for ethical or physiological reasons.
An appropriate choice of experimental design for estimating parameters in NLMEM is re-
quired. NLMEM are also now commonly used for the joint modelling of several biological
responses, such as the joint analysis of the pharmacokinetics (PK) and pharmacodynamics
(PD) of a drug, or the PK of parent drugs and their active metabolites.
Designs in NLMEM are called population designs. Population designs consist of a set of
elementary designs to be carried out in a set of individuals (Mentre´ et al, 1997). Elementary
designs are composed of the design variables to be performed for each individual. Design
variables are for example the number of samples by individual and the location of sampling
times but can be more general. The choice of the design variables and the balance between
the number of individuals and the amount of information by individual have a large impact
on the precision of population parameter estimates. In this work, the sampling times were
considered as the only design variables. Approaches to evaluating and optimizing the designs
are required. To avoid simulations, which are time consuming, designs can be evaluated using
the Fisher information matrix (MF ) and the optimization of its determinant. The expression
of MF for the single-response model was proposed by Mentre´ et al. (1997) and Retout et al.
(2001), using a first-order Taylor expansion of the model around the expectation of random
effects. The expression ofMF for multiple responses was first extended by Hooker and Vicini
(2005), using the same development as for a single-response model. The expression of MF
for nonlinear mixed-effect multiple-response models was also implemented in PFIM, an R
function dedicated to design evaluation and optimization, and was evaluated by simulations
(Bazzoli et al., 2009). Several software packages, which implement an evaluation of the pop-
ulation MF and optimization of the experimental designs in the context of NLMEM, are
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available, notably PFIM in R (Bazzoli et al., 2010).
For MF evaluation, it is often assumed that the variance-covariance matrix of random
effects is diagonal, which means that individual random effects are assumed to be inde-
pendent. The consequence is that covariance terms between parameters are ignored at the
design stage. Ogungbenro et al. (2008) developed an expression of MF that accounts for
covariance between random effects for multiple-response population PK and for population
PK/pharmacodynamics (PD). The objectives of Ogungbenro et al. were to investigate the
implications of including and excluding correlation between random effects and to investigate
the effect of correlation between responses on the optimal sampling times. They performed
a simulation and presented the empirical and expected coefficients of variation of the pa-
rameter estimates for a PK/PD example as well as the mean relative error and root mean
square error for the same example, with and without correlation, to assess the level of bias
and precision of the estimates. The aim of the present work, is to investigate the impact
of the size of covariance between random effects on the optimal sampling-time design for a
pharmacokinetic example and in addition to study its effect on predicted standard errors
(SE), predicted relative standard errors (RSE) and the amount of information, taking into
consideration covariance between random effects. Moreover and conversely to the work of
Ogungbenro et al., in the present work, design optimization allowed several groups of ele-
mentary designs. In addition, it is shown how the SEs in the framework of rich individual
data can be predicted analytically, without using the model. Assuming rich individual data,
it can be assumed that individual parameters of each subject are known without error. Esti-
mation of fixed effects and variance for these parameters is standard and predicted SEs can
be derived analytically.
The results are illustrated by applying these developments to the design of a clinical PK
study in children of a molecule in development. To illustrate the results, a molecule and
its main metabolite were chosen. Indeed, as the parent drug is metabolised into an active
metabolite, concentration-time data of both parent drug and its metabolite are of inter-
est. Developments are applied to the single-response model (parent-drug model) and to the
multiple-response model (joint parent- and metabolite-model). To optimize sampling times,
it is necessary to have a priori information, and in this case, a priori information was model
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and parameters obtained from data generated by the SIMCYP software using the adults-to-
children extrapolation tool, the knowledge of the drug in adults, its physico-chemical proper-
ties and in vitro experimental data. SIMCYP is a software program of Physiologically-Based
PharmacoKinetic (PBPK) modelling (Jamei et al., 2009). PBPK models make it possible to
describe the biodistribution of a substance (absorption, distribution, metabolism, excretion)
and are based on a physiological reality. SIMCYP can predict the evolution of concen-
tration versus time for a given molecule and in a target population (healthy volunteers,
Caucasians, children, etc.). More specifically for the present study, the paediatric module
of SIMCYP took into account all the changes occurring during childhood (Johnson et al.,
2006). Concentration-time profiles for parent and metabolite in children from SIMCYP sim-
ulations have already been analysed by NLMEM with the NONMEM software (Brendel et
al., 2010).
The present article is divided into four sections including the introduction. Section 2
presents the methodological development with notation definitions in 2.1. The calculation of
the SEs of correlation and covariance terms is presented in subsection 2.2, methodology to
approximateMF and the SEs in the framework of individual-rich data is presented in subsec-
tion 2.3. In the fourth subsection (2.4), the focus is on the implementation and optimization
of MF considering covariance between random effects in PFIM. Section 3 first presents the
PK example in paediatrics and the models (3.1). Then, the methods and results concerning
the evaluation of the extension of MF in PFIM are shown (3.2). The two last subsections
present the methods and the results of the approximation of the MF calculation (3.3) and
the impact of covariance on SEs, the amount of information and optimal designs (3.4).
2 METHODOLOGICAL DEVELOPMENT
2.1. Model and notations
A nonlinear mixed-effect multiple-response model, or a multiple response population
model, is defined as follows. The vector of observations Yi for the i
th individual is defined
as the vector of the K different responses: Yi = [y
T
i1, y
T
i2, ..., y
T
iK ]
T , where yik, k = 1, ..., K,
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is the vector of nik observations for the k
th response. Each of these responses is asso-
ciated with a known function fk, which defines the nonlinear structural model. The K
functions fk can be grouped in a vector of multiple-response model F, such as F (θi, ξi) =
[f1(θi, ξi1)
T , f2(θi, ξi2)
T , ..., fK(θi, ξiK)
T ]T , where ξi is an elementary design for one individual
i, composed of K sub-designs such that ξi = (ξi1, ξi2, ..., ξiK). ξi is defined by ni sampling
times and its sub-design ξik is defined by (tik1, tik2, ..., tiknik), with nik sampling times for the
observations of the kth response, so that ni =
K∑
k=1
nik.
θi is the vector of all the individual parameters for all the response models in individual
i. The vector of individual parameters θi depends on β, the p-vector of the fixed effects pa-
rameters and on bi, the vector of the p random effects for individual i. The relation between
θi and (β,bi) is modelled by a function g, that is θi = g(β, bi), which is usually additive, so
that θi = β + bi, or exponential so that θi = exp(β
∗ + bi), where exp(β
∗) = β. It is assumed
that bi ∼ N(0,Ω) with Ω defined as a p×p-positive definite matrix, for which, each diagonal
element ω2rr, r = 1, ..., p, represents the variance of the r
th component of the vector bi and
ωrs, r = 1, ..., p and s = 1, ...p, with r 6= s, represents the covariance between the rth and the
sth components of the vector bi.
The statistical model is then given by Yi = F (g(β, bi), ξi) + εi, where εi is the vector
composed of the K vectors of residual errors εik, k = 1, ..., K, associated with the K re-
sponses. It is also supposed that εik ∼ N(0,Σik) with Σik a nik × nik-diagonal matrix such
that: Σik(β, bi, σinterk , σslopek , ξik) = diag(σinterk + σslopek × fk(g(β, bi), ξik))2 where σinterk
and σslopek are two parameters of the model for the variance of the residual error of the
kth response. The case σslopek = 0 returns a homoscedastic error model, whereas the case
σinterk = 0 returns a constant coefficient of variation error model. The case where the two
parameters differ from zero is called a combined error model. The variance of εi over the K
responses is then noted Σi(β, bi, σinter, σslope, ξi), where Σi is a ni × ni-diagonal matrix com-
posed of each diagonal element of Σik with k = 1, ..., K and σinter and σslope are two vectors
of the K components σinterk and σslopek , k = 1, ..., K, respectively. Finally, conditionnally on
the value of bi, it is assumed that the εi errors are independently distributed.
Let λ be the vector of the unknown variance-covariance terms, corresponding to the vec-
tor of the lower triangular of Ω, which contains p(p+1)/2 variance-covariance terms and all
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the parameters of the error model.
Then, λ is expressed as λT = (ω211, ..., ω
2
pp, ω21, ω31, ω32, ..., ωp,p−1, σ
T
inter, σ
T
slope). Let Ψ be the
vector of the population parameters to be estimated such as ΨT = (βT , λT ).
For N individuals, a population design is composed of the N elementary designs ξi,
i = 1, ..., N . A population design is therefore described by the N elementary designs for a
total number ntot of observations such as ntot =
N∑
i=1
ni and Ξ = {ξ1, ..., ξN}. Usually, popu-
lation designs are composed of a limited number Q of groups of individuals with identical
designs and identical covariates within each group. Each of these groups is defined by an
elementary design ξq, q = 1, ..., Q, which is composed, for the k
th response, especially of
nqk sampling times (tqk1, tqk2, ..., tqknqk) to be performed in a number Nq of individuals. The
population design can then be written as follows: Ξ = {[ξ1, N1]; [ξ2, N2]; ...; [ξQ, NQ]}.
2.2. Calculation of the standard errors of correlation and covariance
The population Fisher information matrix for a population design Ξ is computed as
the sum of the N elementary Fisher information matrices MF (Ψ, ξi) for each individual i:
MF (Ψ,Ξ) =
N∑
i=1
MF (Ψ, ξi). In the case of a limited number Q of groups, it is expressed by
MF (Ψ,Ξ) =
Q∑
q=1
NqMF (Ψ, ξq).
Ogungbenro et al. (2008) have developed the expression ofMF in NLMEM that accounts
for covariance between random effects for multiple responses, i.e. with a non-diagonal Ω
matrix. This expression is implemented in a working version of PFIM and the corresponding
development is detailed in the appendix.
From the square roots of the diagonal elements of M−1F , the predicted SE for estimated
parameters can be calculated. The aim is to predict the SE for estimated correlation, the
correlation being the ratio of the covariance and the product of the standard deviations. It
should be noted that, if ϕ(θ) is a function of θ, thenMF (θ) = JMF (ϕ(θ))J
T , with J = ∂ϕ(θ)
T
∂θ
.
In the following, B11, B22, B33, B12, B13 and B23 are terms of the 3 × 3 sub-matrix of B,
formed of lines and columns corresponding to ωmm, ωll and ωml, respectively. Thus:
SE2(ρ̂ml) = ρ
2
ml(
1
4ω4mm
B−111 +
1
4ω4
ll
B−122 +
1
ω2mmω
2
ll
ρ2
ml
B−133 +
1
2ω2mmω
2
ll
B−112 − 1ω3mmωllρmlB
−1
13 − 1ωmmω3llρmlB
−1
23 )
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And vice versa, if B is now computed as a function of ωmm, ωll and ρml, it becomes
SE2(ω̂ml) = ω
2
ml(
1
4ω4mm
B−111 +
1
4ω4
ll
B−122 +
ω2mmω
2
ll
ω2
ml
B−133 +
1
2ω2mmω
2
ll
B−112 +
ωll
ωmmωml
B−113 +
ωmm
ωllωml
B−123 )
where estimators are designated with ̂.
2.3. Approximation of the Fisher information matrix for rich design
In NLMEM, the parameters themselves are not estimated, but their mean and variance
are. Let’s consider that the vector of individual parameters θi of each subject is known with-
out error, and estimation of β and Ω is performed from this set of N individual parameters.
The SEs for βˆ and Ωˆ can be predicted analytically without using the model and will depend
on the design only through N, the number of subjects, therefore Ξ = N . To derive the
expression of the MF in that case, we assume that we have N vectors of observation θi with
θ ∼ N(β,Ω). In that case, Ψ∗T = (βT , λ∗T ), where λ∗T = vec(Ω). The general term of the
mth line and lth column of the elementary Fisher information matrix for β and Ω is given by
expression:
M∗F (Ψ
∗, N)m,l =
∂βT
∂Ψ∗m
Ω−1
∂β
∂Ψ∗l
+
1
2
tr(Ω−1
∂Ω
∂Ψ∗m
Ω−1
∂Ω
∂Ψ∗l
)
where tr denotes the trace of a matrix.
The derivative of β with respect to fixed effects is equal to 1, and with respect to variance
terms is equal to 0. The derivative of Ω with respect to fixed effects is 0 while the derivative
of Ω with respect to variance terms is equal to a matrix composed of 1 for the corresponding
term and 0 elsewhere. Therefore, the information matrix is block diagonal.
The block ofM∗F for the fixed effects, called block A, is given byM
∗
F (β,N) = Ω
−1. The block
for λ∗, called block B, has the following components: M∗F (λ
∗, N)m,l =
1
2
tr(Ω−1
∂Ω
∂λ∗m
Ω−1
∂Ω
∂λ∗l
),
m, l = 1, ..., dim(λ∗).
The population Fisher information matrix for N individuals is obtained with the above
formula multiplied by N. It is then inverted to obtain SEs.
From these expressions, it can be shown that for β, the diagonal terms of block A−1 are
then equal to 1
N
× ω2mm in the case of additive random effect and to 1N × ω2mm × β2m in the
case of exponential random effect, m = 1, ..., p. The standard errors for the fixed effects are
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therefore given by
SE(β̂m) =
1√
N
× ωmm, for additive random effect,
SE(β̂m) =
1√
N
× ωmm × βm, for exponential random effect, respectively.
For Ω, the diagonal terms of the block B−1 are equal to 1
N
× 2 × ω4mm when the index
corresponds to a variance term and to 1
N
×(ω2mmω2ll+ω2ml) when it corresponds to a covariance
term. The SE of a variance parameter is equal to
SE(ω̂2mm) =
1√
N
×√2× ω2mm
and that of a covariance parameter is
SE(ω̂ml) =
1√
N
×√ω2mm × ω2ll + ω2ml.
Similarly, the results for the correlation can be obtained:
SE(ρ̂ml) =
1√
N
× (1− ρ2ml).
For variance components, the results are the same for additive and exponential random effect
models.
Using this approach, the SEs can be viewed as lower limits of the expected SEs that we
would get in the case of a rich design, where individual parameters are estimated rather
precisely. They are the lower bound of any design Ξ with N subjects.
2.4. Implementation in PFIM and optimization
Having carried out the extension of theMF for NLMEM with covariance between random
effects, the calculation was implemented into a working version of PFIM, making it possible
to evaluate and optimize designs with covariance between random effects for single- and
multiple-response models. The impact of covariance size on SE and amount of information
was examined. The total information was evaluated through the criterion:
criterion = det(MF )
1/P
with P being the total number of parameters in Ψ.
Optimization was performed using the Federov-Wynn algorithm implemented in PFIM. The
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Federov-Wynn algorithm maximises the determinant of MF using statistical design within
a finite set of sampling times. It can be used to optimize both the structure (number of
groups, number of subjects per group, number of samples per group) and the sampling times
from a finite set of times (Retout et al., 2007). Only one elementary design in all patients
(i.e. one group, with a fixed number of samples) can be assumed.
3 EVALUATION VIA A PHARMACOKINETIC EX-
AMPLE IN PAEDIATRICS
3.1. Presentation of the example
In this section, the PK examples, to which the new developments will be applied, are pre-
sented. Data used to derive the models were ”simulated” plasma concentration versus time
in patients between 0 and 25 years old, obtained via the SIMCYP software using the adults-
to-children extrapolation tool, the knowledge of the drug in adults, its physico-chemical
properties and in vitro experimental data (Perdaems et al., 2010). As the parent drug is
metabolised into an active metabolite, concentration-time profiles of both the parent drug
and its active metabolite were predicted in children. The plasma concentration-time profiles
resulted from an intravenous bolus dose of 0.1 mg/kg in 400 children.
After intravenous injection in children, concentration-time data of the parent drug were
described by a 3-compartment model (single-response model), which is written in ordinary
differential equations as follows:


dA1(t)
dt
= k21A2(t) + k31A3(t)− (k12 + k13 + k10)A1(t)
dA2(t)
dt
= k12A1(t)− k21A2(t)
dA3(t)
dt
= k13A1(t)− k31A3(t)
A1, A2 and A3 being the amount of parent drug in the first, second, third compartment
respectively, kij being the distribution rate constant from compartment i to compartment
j. For each compartment, Ci(t) =
Ai(t)
Vi
and C1 is the concentration of the parent drug in
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plasma. According to these notations, initial conditions are: A1(0) = Dose, A2(0) = 0,
A3(0) = 0.
The model is composed of 6 parameters: CLP = k10×V1, which represents the elimination
clearance, Q2 = k12 × V1 = k21 × V2, the inter-compartmental clearance from compartment
1 to compartment 2, Q3 = k13 × V1 = k31 × V3, the inter-compartmental clearance from
compartment 1 to compartment 3, and V1, V2, V3 the volumes of the central compartment
and of the two peripheral compartments, respectively.
The distribution for the parameters was exponential. Inter-individual variabilities were
found on the CLP clearance and on the volume of the central compartment V1 and were
significantly correlated. The residual error model was a combined error model. σinterP
corresponds to the additive error for the parent molecule and σslopeP corresponds to the pro-
portional part. Table 1 shows the parameter values: as the dose was given per kilogram, all
the parameters and dose are expressed by kilogram.
Regarding the multiple-response model, both parent and metabolite concentration-time
profiles were described by a 4-compartment model. Figure 1 represents the model and the
ordinary differential equations describing the model are presented below:


dA1(t)
dt
= k21A2(t) + k31A3(t)− (k12 + k13 + k14 + k10)A1(t)
dA2(t)
dt
= k12A1(t)− k21A2(t)
dA3(t)
dt
= k13A1(t)− k31A3(t)
dA4(t)
dt
= k14A1(t)− k40A4(t)
A4 is the amount of metabolite and C4(t) =
A4(t)
V4
is the metabolite concentration in plasma.
The initial conditions are the same as before, with A4(0) = 0.
For reasons of model identifiability, metabolite volume (V4) was fixed as being the sum
of the three volumes of the parent, that is, V4 = V1 + V2 + V3. As before, CLP represents
the elimination clearance for the parent, CLPM, defined as k14×V1, represents the clearance
from the parent to the metabolite, and CLM, defined as k40× V4, represents the elimination
clearance for the metabolite.
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The parameter distribution was also exponential. Inter-individual variabilities were found
on the CLP, CLPM and CLM clearances, and on the volume of the central compartment of
the parent V1. As some of the corresponding random effects were significantly correlated,
a full covariance matrix for those four parameters was retained. The residual error model
was a combined error model. σinterP (σinterM ) corresponds to the additive error for the parent
molecule (metabolite, respectively) and σslopeP (σslopeM ) its proportional part. The parameter
values are presented in Table 1 and Figure 2 shows the mean PK profiles of the subjects;
the parent on the left, and metabolite on the right.
3.2. Evaluation of the extension of the Fisher information matrix
including covariance between random effects in PFIM
3.2.1. Methods
To evaluate the extension of MF including covariance between random effects in PFIM
for single- and multiple-responses, the results, with and without covariance, predicted by
PFIM were compared with those obtained by both NONMEM and MONOLIX obtained
from simulated data, using the models presented in the previous section. The parameter
values used for the simulation are described in Table 1.
Data was simulated, using a rich design with 22 sampling times at 0.1, 0.2, 0.4, 0.6, 0.8,
1, 1.3, 1.6, 1.8, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16 and 24 hours after dose injection, with
82 subjects and a dose equal to 0.1 mg/kg. The simulations with and without covariance
were performed for both the single-response model (parent drug only) and for the multiple-
response model (joint parent- and metabolite-model). In each case, only one simulation
was performed because we put ourself in the framework of rich design. The model without
covariance was the same as that with covariance, except for the covariance terms, which
were equal to zero. Two estimation methods were used to estimate parameters: First Order
Conditional Estimate with Interaction (FOCEI) method in NONMEM version 6 (Sheiner and
Beal, 1998) and the Stochastic Approximation Expectation-Maximization (SAEM) algorithm
in MONOLIX version 3.2 (Samson et al., 2006). The estimation methods are different
and so too were the calculations of MF . NONMEM estimates the covariance and its SE,
10
whereas MONOLIX estimates the correlation and its SE. Estimating parameters with two
different software programs provides a more accurate evaluation of the prediction using
PFIM to observed SE. Parameter estimates obtained were called N and M for NONMEM
and MONOLIX, respectively, whereas the parameters of the model are called the reference
parameters (P) (Table 1).
The multiple-response model was implemented in PFIM, whereas the single-response
model was available in the PFIM library (Dubois et al., 2011). The SE of parameters
predicted by PFIM for the 2 models using the reference parameter values (Table 1) were
then compared to SEs obtained by NONMEM and MONOLIX. Given that MONOLIX gives
the SE of correlation and not of covariance, the SE of covariance was then derived by the
approach detailed in section 2.3.
Moreover, a comparison between results obtained by PopDes, the software for optimal
design developed by Ogungbenro et al. (Gueorguieva et al., 2007), and results obtained by
PFIM, was performed for the multiple-response model with and without covariance.
3.2.2. Results
The objective was to compare the SEs predicted by PFIM to those obtained with both
NONMEM and MONOLIX, in both cases, i.e., with and without covariance. Table 2 presents
the reference parameters with and without covariance of the single-response model (par-
ent molecule model), as well as the parameter estimates obtained with NONMEM (N) and
MONOLIX (M). The SEs predicted by PFIM, and those obtained by NONMEM and MONO-
LIX with and without covariance for the PK model of the parent molecule, are also shown in
Table 2. First of all, it can be seen that all parameters were accurately estimated and close
to the reference parameter values. The SE values obtained in the case of the model without
covariance with NONMEM and MONOLIX were very close to those predicted by PFIM for
the single-response model. The largest difference between the SE of parameters was for Q3
between MONOLIX and both PFIM and NONMEM, and was equal to 0.030. It corresponds
to a relative standard error (RSE) equal to 12% for both PFIM and NONMEM and to 9%
for MONOLIX. Similar differences were observed for the RSE of variance parameters (an
absolute difference respectively equal to 3% and 4% between the RSEs for the variances of
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CLP and V1 obtained from PFIM and those obtained from MONOLIX). It can be observed
that the differences between the SE of the other parameters were small (lower than 0.010).
In the case of model with covariance, the SEs given by NONMEM and MONOLIX were also
very close to the SE predicted by PFIM (the largest difference is still for Q3 and is equal to
0.020 between NONMEM and MONOLIX and to 0.010 between PFIM and NONMEM). In
terms of RSE, the differences between PFIM, NONMEM and MONOLIX for Q3 were very
small since the RSEs were equal to 12%, 12% and 11%, respectively. For the covariance term,
the difference between the SE predicted by PFIM and the SEs obtained by both NONMEM
and MONOLIX was equal to 0.0060, which is small. The main differences regarding the
RSE of parameters were for the variance and covariance terms: the largest difference was
equal to 10% between PFIM and NONMEM for the variance of V1. The SEs predicted by
PFIM were similar to those obtained with NONMEM and MONOLIX, in both cases, with
and without covariance, for the single-response model. Moreover, it was observed that the
SEs of parameters were almost identical with and without covariance for PFIM, whether
for fixed effects or variance components. The same results can be observed from the SEs
obtained for both NONMEM and MONOLIX.
Table 3 displays the parameters and corresponding SE predicted by PFIM and obtained
with NONMEM and MONOLIX, with and without covariance, for the PK model of parent
and metabolite. The same conclusions can be drawn with the multiple-response model. As
for the single-response model, it can be noted that PFIM accurately predicted the SE with
and without covariance when compared to both NONMEM and MONOLIX. For some co-
variance terms corresponding to very small correlations, it was observed that the parameter
values estimated by NONMEM and MONOLIX were different from the simulated values.
However, the SEs of the parameters that were predicted by PFIM were in a similar range
to those obtained with NONMEM and MONOLIX, with and without covariance, for the
multiple-response model. Same conclusions are observed for the RSE. Moreover, the predic-
tions were identical for the fixed effects and variance parameters, with and without covari-
ance.
It has therefore been demonstrated that the development ofMF for covariance terms and
its implementation in a working version of PFIM in R were satisfactory because the SEs of
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parameters predicted by PFIM were similar to those obtained with NONMEM and MONO-
LIX, and that was also true for the SE of covariance terms. Table 4 also shows a comparison
of RSEs obtained by PopDes and RSEs obtained by PFIM, for the multiple-response model
with and without covariance. This evaluation shows the appropriateness of the extension
of the population Fisher information matrix with covariance in PFIM. Moreover, it was ob-
served that the results with covariance were similar to those without covariance for the SE
and RSE of fixed effects and variance components.
3.3. Evaluation of approximation of the Fisher information matrix
for rich design
To evaluate the results of the approximation of MF in the framework of individual-rich
data, the SEs obtained by analytical predictions, using the formula of section 2.3 assuming N
= 82, were compared with those predicted by PFIM for both single- and multiple-response
models for the parameters with inter-individual variability (Table 5). This approach can
only be applied to parameters with non-null variance of random effects.
The analytical SEs were very close to the SE predicted by PFIM for both single- and
multiple-response models. The results obtained by analytical predictions assuming rich data
were similar to those given by PFIM using the model on a rich design and the same number
of patients. They represent the lower limits of what could be observed with a sparse design.
3.4. Influence of covariance on designs
3.4.1 Methods
First, the impact of the size of covariance on the SEs, the RSEs and the amount of in-
formation for the single-response model (parent-drug model) was considered. Using PFIM,
the SE and the RSE on fixed effects and variance components assuming different values of
covariance between the two random effects, i.e. CLP and V1, were predicted. The influence
of the covariance on SE, RSE and amount of information was tested on a range of covariance
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from -0.12 to 0.12 (correlation from -0.9 to 0.9).
Second, the sampling time optimization for both the single- and multiple-response mod-
els with and without covariance is taken into consideration. The impact of covariance was
studied on an optimal design with 6 sampling times out of 12 for the single-response model
and with 4 out of 12 for the multiple-response model. For the latter, both response measure-
ments (i.e. parent and metabolite concentrations) were carried out at each sampling time,
i.e. a total of 8 measurements. The number of measurements was chosen depending on the
number of fixed effects, 6 for the parent model and 8 for the joint parent and metabolite
model. The design domain took place over a 24-hour period with allowed sampling times at
0.1, 0.2, 0.4, 0.8, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dose injection.
Sampling time optimization was performed using the Federov-Wynn algorithm imple-
mented in PFIM, which makes it possible to test for design with only one group (one) or
with several groups (several). Optimal designs for the single-response model (single) and
the multiple-response model (multiple) without covariance (nocov) were studied, as well as
the covariance values of Table 1 (cov). For the single-response model, which had a covari-
ance equal to 0.10, design was optimized for a covariance of 0.12 (highcov), correspond-
ing to a correlation of 0.9. Optimizing design with the highest covariance value makes it
possible to be in the furthest case and thus to have an idea of the impact of the covari-
ance value when the latter is high. The corresponding designs were called Ξsingle nocov one,
Ξsingle cov one, Ξsingle highcov one, Ξsingle nocov several, Ξsingle cov several, Ξsingle highcov several for the
single-response model and Ξmulti nocov one, Ξmulti cov one, Ξmulti nocov several and Ξmulti cov several
for the multiple-response model. Then, the optimized designs obtained with and with-
out covariance were evaluated considering a model with a covariance equal to 0.12 for the
single-response model and with covariance terms of Table 1 for the multiple-response model.
Therefore, the optimized designs obtained with and without covariance were then evaluated
taking into consideration a model with covariance, i.e. the same model was used with these
two different designs, concerning the parent in a first time and concerning both parent and
metabolite in a second time. The focus was then on the relative standard error (RSE) of
parameters and the criterion.
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3.4.2 Results
As expected, regardless of the value of covariance between -0.12 and 0.12, the SEs and
the RSEs for fixed effects, variances and error terms were similar (results not shown). Figure
3 shows how the covariance had an impact on the SE and the RSE of covariance and the
amount of information. The SEs of covariance increased for large values of covariance, but
were similar for covariance between -0.03 and 0.03. On the other hand, the RSE decreased
and the amount of information increased for large value of covariance.
Focus on the influence of covariance on optimal designs: for the single-response model
and one group, the optimized designs with 6 times were identical for a covariance equal to
0 and equal to 0.10 (covariance value of Table 1) and the optimal sampling times were 0.1,
0.4, 0.8, 2, 6 and 16 hours after dose injection (Ξsingle nocov one and Ξsingle cov one). For the
Ξsingle highcov one design, where cov = 0.12, the optimal sampling times were the same as those
of the Ξsingle nocov one and Ξsingle cov one designs, except for the second sampling time which
was 0.2 instead of 0.4. These designs were then evaluated taking into consideration a model
with covariance equal to 0.12. Figure 4 shows the RSE of parameters obtained for each
design. It can be seen that the RSEs were very similar between these two evaluations. The
criterion, was equal to 1955 for evaluation of the Ξsingle nocov one and Ξsingle cov one designs,
and 1971 for evaluation of the Ξsingle highcov one design. So, the efficiency loss was minor as it
was below 1%.
Concerning the comparison of the optimal Ξsingle nocov several and Ξsingle highcov several de-
signs: Table 6 shows the elementary design and the number of subjects for the two different
designs. As previously demonstrated, several optimal sampling times obtained were not the
same, whether taking into consideration the covariance or not. However, similar to the op-
timizations with one group, when the criteria were compared between the Ξsingle nocov several
and Ξsingle highcov several designs, respectively, equal to 1996 and 2025, the efficiency loss was
very low (1.5%). Therefore, even if the optimal designs were not exactly the same with or
without covariance, the design efficiency was barely affected.
Focus on the influence of the covariance on optimal designs for the multiple-response
model: one optimal sampling time differed between the Ξmulti nocov one and the Ξmulti cov one
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designs. The Ξmulti nocov one design was composed of optimal sampling times at 0.2, 2, 8 and
24 hours after dose injection and in the Ξmulti cov one design, the second sampling time was
not at 0.2 but rather at 0.1. Then, these two optimal designs were evaluated with a covari-
ance term model. It was observed that RSEs were very similar between the Ξmulti nocov one
and Ξmulti cov one designs, be it for fixed effect parameters, variance parameters or covari-
ance terms. Moreover, when the two criteria obtained for these two designs were compared,
they were equal to 1612 (Ξmulti nocov one design) and 1622 (Ξmulti cov one design), respectively.
Therefore, the efficiency loss here was still below 1%.
Considering several groups of subjects with 4 sampling times, Table 7 shows the differ-
ent elementary designs with the corresponding number of subjects. The number of groups
was different and some groups were present in the Ξmulti nocov several design and not in the
Ξmulti cov several design and vice versa. Evaluating these designs with a covariance model,
the RSEs of Ξmulti nocov several design and the RSEs of Ξmulti cov several design were very sim-
ilar. Similarly, the criteria for these two designs were equal to 1747 and 1758, respectively.
Therefore, the efficiency loss here is still minor (lower than 1%).
4 DISCUSSION
The first objective was to extend the Fisher information matrix in PFIM software for
covariance between random effects and to evaluate it. For the evaluation, a comparison of
the SEs of parameters predicted by PFIM and those given by two nonlinear mixed effect
estimation software, NONMEM and MONOLIX, was carried out. To that end, data were
simulated, using a rich design with 22 sampling times, a dose equal to 0.1 mg/kg in 82 indi-
viduals and with the single-response model and a more complex joint parent and metabolite
model. Only one simulation was performed, it should not affect the results because it is a
rich design with many subjects, so only very little changes are expected across replication.
Also, the objective was the comparison between observed SE and predicted SE and not an
evaluation of empirical SE. This comparison showed agreement between results predicted by
PFIM and those obtained by both the NONMEM and MONOLIX software.
To carry out an optimal design, it is necessary to have a priori information, and in this
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paediatric example, the a priori information was model and parameters obtained from data
generated by the SIMCYP software. The population PK models were fitted to the predicted
SIMCYP data, which were ”simulated” plasma concentration versus time for a parent drug
and its active metabolite.
Then, the impact of the size of covariance was studied. In their work, Ogungbenro et
al. (2008) showed that RSE were very similar for fixed effect parameters, while for variance
parameters, they are slightly higher for design without covariance compared to design with
covariance, especially for pharmacodynamic parameters. Regarding the SEs for the present
work, they did not differ for the fixed parameters or the variance parameters, no matter
the size of the covariance. Similarly, regardless of the value of covariance, the RSEs did
not differ for the fixed parameters or the variance parameters. Therefore, it is perhaps not
necessarily useful to incorporate covariance in design stage for those parameters. But further
comparisons would be needed. On the other hand, it was observed that the SE of covariance
increased when covariance was large whereas the RSE of covariance decreased. Concerning
the amount of information, it increased for very large values of covariance. The amount of
information was lower without covariance, which means that the corresponding MF was a
lower limit of the information computed with covariance terms.
Concerning the approximation of the calculation of the SEs without using the model,
which mimics the case of individual-rich data, it was possible to obtain an idea of the pre-
cision of estimates quickly, and to see if the number of subjects was large enough. Indeed,
these analytical predictions were the lower limits of the SEs that could be obtained by the
population approach, and could not be improved by increasing the number of samples per
patient.
Focusing then on the influence of covariance on optimal designs, as Ogungbenro et al.
(2008) demonstrated, it was shown that optimal design depends on the covariance between
parameters. Indeed, the values of covariance terms can affect optimal sampling times, how-
ever it was rather slight in the case of a one-group design. When considering several groups
of subjects, optimal sampling times and groups can be different with and without covari-
ance, but the efficiency loss was very low for both one group and several groups. Further
comparisons should be performed. Also, the design variables chosen in this work were the
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location of sampling times but it would be possible to extend to other design variables, as
for example the dose (Nyberg et al., 2009).
In the present work, the calculation of MF was proposed using a first-order linearization
of the model by the Taylor expansion. The derivative of the variance of observations accord-
ing to β was assumed to be zero. Therefore, MF was expressed as a block diagonal matrix.
An extension of MF considering the dependence of the observations on the parameters of
the model, that is, a complete MF with an additional off-diagonal block, was also proposed
(Retout and Mentre´, 2003). However, Mentre´ et al. (2011) showed on two examples that if
a linearization of the model was carried out, it is better to have a block diagonal expression
for MF . Mielke and Schwabe (2010) also showed that an approach with block diagonal MF
was more reliable than one with the full MF . But it is not the case for all situations, as
shown by Nyberg et al. (2008). In the MONOLIX software, the observed MF calculated by
linearization of the model also had a block diagonal expression. It is known that linearization
can lead to problems when a very nonlinear model is used. An alternative to linearization,
for example the Gaussian quadrature (Guedj et al., 2007; Nguyen et al., 2011), could also
be developed for models with covariance.
In conclusion, the extension of MF including covariance between random effects in PFIM
provides a useful computing tool for design evaluation and optimization, and this extension
will be available in the next version of PFIM. The size of covariance had no impact on the
SE of fixed effects or variance parameters. Omitting the covariance at the design stage influ-
enced the optimal sampling times, but barely had an influence on efficiency, and predicted
SEs were only slightly changed.
5 APPENDIX
The Fisher information matrixMF (Ψ, ξi) for multiple-response models for the individual
i with design ξi is given by MF (Ψ, ξi) = E(−∂
2Li(Ψ;Yi)
∂Ψ∂ΨT
), where Li(Ψ;Yi) is the log-likelihood
of the vector of observations Yi of that individual for the population parameters Ψ. Because
F is nonlinear, there is no analytical expression for the log-likelihood and a first-order Taylor
expansion of the model F (θi, ξi) = F (g(β, bi), ξi), around the expectation of bi, that is to say
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around 0, is used: F (g(β, bi), ξi) ∼= F (g(β, 0), ξi) + (∂F
T (g(β,bi),ξi)
∂bi
)bi=0bi.
Therefore, Yi ∼= F (g(β, 0), ξi) + (∂F
T (g(β,bi),ξi)
∂bi
)bi=0bi + εi.
Using this linearization, the approximated marginal expectation Ei and variance Vi of Yi are
given by:
E(Yi) ∼= Ei = F (g(β, 0), ξi)
V ar(Yi) ∼= Vi = (∂F
T (g(β, bi), ξi)
∂bi
)bi=0Ω(
∂F (g(β, bi), ξi)
∂bTi
)bi=0 + Σ(β, 0, σinter, σslope, ξi)
The log-likelihood Li is approximated by:
−2Li(Ψ;Yi) ∼= niln(2pi) + ln(|Vi|) + (Yi − Ei)TV −1i (Yi − Ei)
The elementary Fisher information matrix for a multiple-response model with non-diagonal
variance matrix is derived from this expression of the log-likelihood. In the following, the i
index for the individual is omitted for the sake of simplicity.
MF (Ψ, ξ) = EY (−∂
2(L(Ψ, Y )
∂Ψ∂ΨT
)
The elementary MF depends on the approximated marginal expectation E and variance V
of the observations. Assuming that the derivative of V does or does not depend on the fixed
effects, the elementary MF is a full matrix or a block diagonal matrix. It was suggested
(Mentre´ et al., 2011; Mielke and Schwabe, 2010) that for derivation of MF using first-order
linearization, the block diagonal expression might be better. This is not always the case, as
presented by Nyberg et al. (2008). Here, the block diagonal expression for MF was chosen
and is expressed as:
MF (Ψ, ξ) ∼= 12

A(E, V ) 0
0 B(E, V )


where
(A(E, V ))ml = 2
∂F T
∂βm
V −1
∂F
∂βl
with m and l = 1, ..., p and
(B(E, V ))ml = tr(
∂V
∂λm
V −1
∂V
∂λl
V −1)
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with m and l = 1, ..., dim(λ).
The calculations of the Fisher information matrix with all covariance terms in Ω were
developed. For block A, it is the same calculation with and without covariance, except that
the Ω matrix is full when covariance is considered. On the other hand, the calculations are
different for block B. Indeed
∂V
∂λm
= (
∂F T (g(β, b), ξ)
∂b
)b=0
∂Ω
∂λm
(
∂F (g(β, b), ξ)
∂bT
)b=0 + (
∂Σ(β, b, σinter, σslope, ξ)
∂λm
)b=0
with m = 1, ..., dim(λ).
And depending on whether m corresponds to a variance or covariance term, ∂Ω
∂λm
contains
one or two terms different from zero, respectively. For a variance term, that is for λ1 to λp
(corresponding to ω211 to ω
2
pp), the general term for the derivation of the matrix V according
to λm, m varying from 1 to p, for one response, is expressed as:
∂fk(g(β, 0), tj)
∂bm
∂fk(g(β, 0), tj′)
∂bm
with j = 1, ..., nk the line index, j
′ = 1, ..., nk the column index and k corresponding to the
kth response.
For a covariance term from λp+1 to λp(p+1)/2 (corresponding to ω21 to ωp,p−1), the deriva-
tion of the matrix V, for one response, according to λm is expressed as:
∂fk(g(β, 0), tj)
∂br
∂fk(g(β, 0), tj′)
∂bs
+
∂fk(g(β, 0), tj)
∂bs
∂fk(g(β, 0), tj′)
∂br
with r, s = 1, ..., p, r 6= s, j = 1, ..., nk the line index, j′ = 1, ..., nk the column index, and k
corresponding to the kth response.
Note that (
∂Σ(β,b,σinter,σslope,tj)
∂λm
)b=0 is equal to zero when m does not correspond to an
item of an error parameter. Otherwise, the derivation of the matrix V according to λm,
λm = σinterk , is equal to 2 × diag(σinter + σslope × fk(g(β, 0), tj)) and the derivation of the
matrix V according to λm = σslopek is 2× diag(fk(g(β, 0), tj)(σinter+σslope× fk(g(β, 0), tj))),
with j = 1, ..., nk and k corresponding to the k
th response.
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Table 1: Population pharmacokinetic parameter values for the parent drug and the joint
model of the parent drug and its metabolite
Parameters (units) Parameter values
Parent drug Joint model
βCLP (L.h
−1.kg−1) 0.81 0.61
βCLPM (L.h
−1.kg−1) - 0.11
βV1 (L.kg
−1) 0.88 0.97
βQ2 (L.h
−1.kg−1) 0.58 0.12
βV2 (L.kg
−1) 1.0 0.41
βQ3 (L.h
−1.kg−1) 1.3 0.69
βV3 (L.kg
−1) 0.39 0.87
βCLM (L.h
−1.kg−1) - 0.91
ω2CLP 0.23 0.25
ω2CLPM - 1.4
ω2V1 0.075 0.070
ω2CLM - 0.27
ωCLP,V1 0.10 0.045
ωCLP,CLPM - 0.036
ωV1,CLPM - 0.024
ωCLP,CLM - 0.091
ωV1,CLM - 0.083
ωCLPM,CLM - -0.045
σinterP (µg.L
−1) 0.22 0.072
σslopeP 0.10 0.16
σinterM (µg.L
−1) - 0.011
σslopeM - 0.053
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Table 2: SE of the parameters with and without covariance predicted by PFIM (P), and obtained by NONMEM (N) and
MONOLIX (M) on a simulated data set for the parent molecule and the rich design in 82 patients (22 observations per patient)
Model without covariance Model with covariance
Reference Estimated Predicted Obtained Reference Estimated Predicted Obtained
parameters parameters SE SE parameters parameters SE SE
Parameters P N M P N M P N M P N M
βCLP 0.81 0.87 0.87 0.043 0.052 0.051 0.81 0.88 0.87 0.043 0.053 0.053
βV1 0.88 0.88 0.88 0.037 0.037 0.037 0.88 0.91 0.89 0.037 0.042 0.040
βQ2 0.58 0.56 0.53 0.031 0.029 0.030 0.58 0.55 0.54 0.031 0.034 0.030
βV2 1.0 1.0 1.0 0.024 0.022 0.025 1.0 1.0 1.0 0.024 0.026 0.025
βQ3 1.3 1.3 1.3 0.15 0.15 0.12 1.3 1.4 1.4 0.15 0.16 0.14
βV3 0.39 0.39 0.41 0.027 0.021 0.026 0.39 0.40 0.41 0.027 0.025 0.027
ω2
CLP
0.23 0.28 0.28 0.036 0.038 0.044 0.23 0.30 0.30 0.036 0.039 0.047
ω2
V1
0.075 0.086 0.088 0.013 0.015 0.016 0.075 0.097 0.098 0.013 0.020 0.017
ωCLP,V1 (ρCLP,V1 ) - - - - - - 0.10(0.78) 0.14(0.84) 0.14(0.84) 0.019 0.025 0.025
σinterP 0.22 0.28 0.22 0.011 0.011 0.011 0.22 0.28 0.22 0.011 0.011 0.011
σslopeP 0.10 0.13 0.11 0.0020 0.0030 0.0030 0.10 0.13 0.11 0.0025 0.0025 0.0028
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Table 3: SE of the parameters with and without covariance predicted by PFIM (P), and obtained by NONMEM (N) and
MONOLIX (M) on a simulated data set for parent and metabolite and the rich design in 82 patients (22 observations per
patient)
Model without covariance Model with covariance
Reference Estimated Predicted Obtained Reference Estimated Predicted Obtained
parameters parameters SE SE parameters parameters SE SE
Parameters P N M P N M P N M P N M
βCLP 0.61 0.67 0.67 0.034 0.041 0.040 0.61 0.68 0.67 0.034 0.041 0.041
βV1 0.97 0.97 0.95 0.030 0.028 0.027 0.97 0.98 0.98 0.030 0.026 0.026
βQ2 0.12 0.098 0.13 0.044 0.038 0.045 0.12 0.11 0.14 0.044 0.041 0.047
βV2 0.41 0.37 0.44 0.093 0.079 0.089 0.41 0.39 0.47 0.093 0.083 0.094
βQ3 0.69 0.69 0.65 0.037 0.031 0.038 0.69 0.68 0.65 0.037 0.034 0.041
βV3 0.87 0.89 0.80 0.097 0.085 0.094 0.87 0.86 0.78 0.097 0.089 0.099
βCLPM 0.11 0.11 0.11 0.015 0.015 0.015 0.11 0.11 0.11 0.015 0.015 0.016
βCLM 0.91 0.93 0.91 0.054 0.048 0.050 0.91 0.95 0.95 0.054 0.048 0.050
ω2
CLP
0.25 0.30 0.29 0.040 0.039 0.046 0.25 0.30 0.30 0.040 0.037 0.046
ω2
V1
0.070 0.063 0.056 0.012 0.012 0.010 0.070 0.053 0.048 0.012 0.011 0.0090
ω2
CLPM
1.4 1.6 1.6 0.21 0.22 0.25 1.4 1.6 1.6 0.21 0.22 0.25
ω2
CLM
0.27 0.23 0.23 0.043 0.036 0.036 0.27 0.21 0.21 0.043 0.039 0.034
ω(CLP,V1)(ρCLP,V1 ) - - - - - - 0.045(0.34) 0.044(0.35) 0.043(0.36) 0.016 0.012 0.014
ωCLP,CLPM (ρCLP,CLPM ) - - - - - - 0.036(0.061) 0.13(0.19) 0.12(0.18) 0.065 0.073 0.077
ωV1,CLPM (ρV1,CLPM ) - - - - - - 0.024(0.078) -0.015(-0.052) -0.0050(-0.018) 0.036 0.040 0.031
ωCLP,CLM (ρCLP,CLM ) - - - - - - 0.091(0.35) 0.082(0.33) 0.081(0.32) 0.031 0.028 0.029
ωV1,CLM (ρV1,CLM ) - - - - - - 0.083(0.61) 0.052(0.49) 0.049(0.49) 0.019 0.017 0.012
ωCLPM,CLM (ρCLPM,CLM ) - - - - - - -0.045(-0.075) -0.14(-0.23) -0.13(-0.22) 0.068 0.073 0.066
σinterP 0.072 0.095 0.076 0.0061 0.0045 0.0052 0.072 0.094 0.076 0.0061 0.0047 0.0052
σslopeP 0.16 0.19 0.17 0.0032 0.0031 0.0036 0.16 0.19 0.17 0.0032 0.0030 0.0036
σinterM 0.011 0.015 0.011 0.00082 0.00073 0.00062 0.011 0.014 0.012 0.00082 0.00064 0.00062
σslopeM 0.053 0.057 0.049 0.0014 0.0012 0.0013 0.053 0.057 0.049 0.0014 0.0011 0.0013
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Table 4: RSE (%) of the parameters with and without covariance predicted by PopDes and PFIM for the parent and metabolite
and the rich design in 82 patients (22 observations per patient)
Model without covariance Model with covariance
Parameters Parameter values PopDes PFIM Parameter values PopDes PFIM
βCLP 0.61 5.6 5.6 0.61 5.6 5.6
βV1 0.97 3.0 3.1 0.97 3.0 3.1
βQ2 0.12 32 38 0.12 32 38
βV2 0.41 20 23 0.41 20 23
βQ3 0.69 4.7 5.4 0.69 4.7 5.4
βV3 0.87 9.7 11 0.87 9.7 11
βCLPM 0.11 13 13 0.11 13 13
βCLM 0.91 5.8 5.8 0.91 5.8 5.8
ω2
CLP
0.25 16 16 0.25 16 16
ω2
V1
0.070 17 17 0.070 17 17
ω2
CLPM
1.4 16 16 1.4 16 16
ω2
CLM
0.27 16 16 0.27 16 16
ω(CLP,V1) - - - 0.045 35 36
ωCLP,CLPM - - - 0.036 183 183
ωV1,CLPM - - - 0.024 147 148
ωCLP,CLM - - - 0.091 34 34
ωV1,CLM - - - 0.083 22 22
ωCLPM,CLM - - - -0.045 151 151
σinterP 0.072 7.7 8.3 0.072 7.7 8.3
σslopeP 0.16 1.8 2.0 0.16 1.8 2.0
σinterM 0.011 5.1 5.3 0.011 5.1 5.3
σslopeM 0.053 2.0 2.4 0.053 2.0 2.4
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Table 5: Comparison of SEs obtained by analytical predictions and SEs predicted by PFIM
for both single- and multiple-response models for the parameters with inter-individual vari-
ability, in the framework of rich design in 82 patients (22 observations per patient)
Single-response model Multiple-response model
Parameters Parameter Analytical PFIM Parameter Analytical PFIM
values predictions predictions values predictions predictions
βCLP 0.81 0.043 0.043 0.61 0.034 0.034
βV1 0.88 0.027 0.027 0.97 0.028 0.028
βCLPM - - - 0.11 0.014 0.014
βCLM - - - 0.91 0.052 0.052
ω2
CLP
0.23 0.036 0.036 0.25 0.039 0.039
ω2
V1
0.075 0.012 0.012 0.070 0.011 0.011
ω2
CLPM
- - - 1.4 0.22 0.22
ω2
CLM
- - - 0.27 0.042 0.042
ω(CLP,V1) 0.10 0.018 0.018 0.045 0.015 0.015
ωCLP,CLPM - - - 0.036 0.065 0.065
ωV1,CLPM - - - 0.024 0.035 0.035
ωCLP,CLM - - - 0.091 0.030 0.030
ωV1,CLM - - - 0.083 0.018 0.018
ωCLPM,CLM - - - -0.045 0.068 0.068
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Table 6: Optimal designs with 6 points with several groups for the single-response model:
Ξsingle nocov several design is for a model with covariance = 0 and Ξsingle highcov several design
for a model with covariance = 0.12
Time (in hour) Number of subjects
Ξsingle nocov several Ξsingle highcov several
0.1, 0.2, 0.4, 2, 6, 16 0 16
0.1, 0.2, 0.8, 2, 6, 16 0 28
0.1, 0.2, 0.8, 4, 12, 16 5 22
0.1, 0.4, 0.8, 2, 4, 12 5 14
0.1, 0.4, 0.8, 2, 6, 16 52 0
0.1, 0.4, 1, 4, 12, 16 18 0
0.1, 0.4, 2, 6, 16, 24 2 2
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Table 7: Optimal designs with 4 points with several groups for the multiple-response model:
Ξmulti nocov several design is for a model with every covariance = 0 and Ξmulti cov several design
with at least one covariance 6= 0 (see Table 1)
Time (in hour) Number of subjects
Ξmulti nocov several Ξmulti cov several
0.1, 0.8, 4, 12 22 21
0.1, 0.8, 12, 24 3 2
0.1, 2, 6, 16 0 5
0.1, 2, 8, 24 37 42
0.1, 2, 12, 24 0 2
0.1, 6, 16, 24 14 10
0.2, 2, 8, 24 1 0
0.8, 4, 12, 24 4 0
2, 6, 16, 24 1 0
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Figure 1: Structural PK model with 4 compartments: 3 compartments for the parent drug
and one additional compartment for the metabolite.
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Figure 2: Mean concentration-time profiles for the parent (left) and for the metabolite (right)
for 22 sampling times per subject.
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Figure 3: Influence of covariance on SE (left, ) and RSE (right, •) of covariance for the
single-response model (top), and influence of covariance on criterion for the single-response
model (bottom).
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Figure 4: Predicted RSE (%) of fixed effect parameters (top) and variance components
(bottom) for Ξsingle nocov one and Ξsingle cov one designs in black (optimized with a covariance
= 0 and with a covariance = 0.10) and the Ξsingle highcov one design in white (optimized with
covariance = 0.12) for the single-response model with covariance = 0.12.
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